<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Because the potential neuroprotective effect of <z:chebi fb="0" ids="6015">isoflurane</z:chebi> is controversial, we attempted to study whether <z:chebi fb="0" ids="6015">isoflurane</z:chebi> after treatment provides neuroprotection in a rat model of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced ischemic hemorrhagic transformation </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Rats received an injection of 50% <z:chebi fb="10" ids="4167">dextrose</z:chebi> (6 mL/kg intraperitoneally) and had a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> 30 minutes later </plain></SENT>
<SENT sid="2" pm="."><plain>Four groups were included: sham-operated, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion, <z:chebi fb="0" ids="6015">isoflurane</z:chebi> treatment, and vehicle groups </plain></SENT>
<SENT sid="3" pm="."><plain>In the treatment group, after 2 hours of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, 2% <z:chebi fb="0" ids="6015">isoflurane</z:chebi> was administered at the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>We measured the level of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> at 0, 2.5, 4.5, and 6.5 hours after <z:chebi fb="10" ids="4167">dextrose</z:chebi> injection </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> and hemorrhagic volumes, neurological scores, <z:mp ids='MP_0003674'>oxidative stress</z:mp> (malondialdehyde, <z:chebi fb="0" ids="32585">4-hydroxy-2-nonenal</z:chebi>, and nitrotyrosine) and the activities of <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and catalase were measured at 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6015">Isoflurane</z:chebi> had no effects on blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, it failed to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath>, <z:mp ids='MP_0001914'>hemorrhage</z:mp> volume, and <z:hpo ids='HP_0002181'>brain edema</z:hpo>, and it enhanced neurobehavioral deficits when compared with the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion group at 24 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>On the contrary, <z:chebi fb="0" ids="6015">isoflurane</z:chebi> exacerbated these parameters compared with the vehicle group </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, it increased the expressions of malondialdehyde, <z:chebi fb="0" ids="32585">4-hydroxy-2-nonenal</z:chebi>, and nitrotyrosine, and it decreased the activities of <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and catalase compared to the vehicle group </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6015">Isoflurane</z:chebi> after treatment worsened physiological and neurological outcomes in this <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced hemorrhagic transformation possibly by impairing the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> defense system </plain></SENT>
</text></document>